Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Rezjenon Mar 02, 2021 1:32pm

312 Views

Post# 32696197

Dig deeper, connect dots - R107 a head than the NRs

Company worked past 6-9 months with Focus in R107 only, no one can update the market in one news report... lots of update/ news in the pipeline.

lucky to add more at 6c today

profit takers are taking exist, and many will chase!

smart is accumulating at this level and why not? When you know all the thing company is doing- new website, social media, 3 NRs in three consecutive days, volume -- all these are indicators guys---

do more DD, as I said earlier - many here will be millionaires from this stock!

<< Previous

Bullboard Posts

Next >>

Canada Goose appoints first creative director